Cardiometabolic effects of a novel SIRT1 activator, SRT2104, in people with type 2 diabetes mellitus

BACKGROUND: The cardiometabolic effects of SRT2104, a novel SIRT1 activator, were investigated in people with type 2 diabetes mellitus (T2DM). METHODS: Fifteen adults with T2DM underwent a randomised, double-blind, placebo-controlled cross-over trial and received 28 days of oral SRT2104 (2.0 g/day)...

Descripción completa

Detalles Bibliográficos
Autores principales: Noh, Radzi M, Venkatasubramanian, Sowmya, Daga, Shruti, Langrish, Jeremy, Mills, Nicholas L, Lang, Ninian N, Hoffmann, Ethan, Waterhouse, Brian, Newby, David E, Frier, Brian M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Basic and Translational Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5588958/
https://www.ncbi.nlm.nih.gov/pubmed/28912956
http://dx.doi.org/10.1136/openhrt-2017-000647

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5588958/
https://www.ncbi.nlm.nih.gov/pubmed/28912956
http://dx.doi.org/10.1136/openhrt-2017-000647

Ejemplares similares